JPRN-jRCTs071190043已完成未知
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy - ESES-LVH study
Tsujita Kenichi0 个研究点目标入组 60 人开始时间: 2020年1月24日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
Esaxerenone showed stable antihypertensive effect and regression effect on left ventricular hypertrophy (reduction of LVMI) regardless of the kind of basal antihypertensive agent (RA inhibitor or CCB). No new unpredictable AEs or ADRs were observed, and safety of esaxerenone have been confirmed. It is suggested that esaxerenone can be clinically useful option as the second-line treatment for hypertensive patients with cardiac hypertrophy who had uncontrolled BP under treatment with RA inhibitor or CCB.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients with hypertension (early morning home blood pressure [BP]: =>135 mmHg and <=159 mmHg of systolic blood pressure and/or =>85 mmHg and <=99 mmHg of diastolic blood pressure)
- •2)Patients with left ventricular hypertrophy.
- •3)Patients treated with renin-angiotensin inhibitor or Ca-antagonist.
- •4)Patients aged 20 years or older.
排除标准
- •1)Patients with a diagnosis of secondary hypertension or malignant hypertension.
- •2)Patients with orthostatic hypotension or a history of orthostatic hypotension.
- •3)Patients with any of the cerebro-cardiovascular diseases.
- •4)Patients with type 1 diabetes.
- •5)Hyperkalemia patients, patients whose serum potassium level exceeds 5.0 mEq/L, etc.
- •6)Patients who the investigator judges to be unsuitable for the study.
研究者
相似试验
已完成
不适用
EX-DKD studyJPRN-jRCTs061190027Wada Jun113
已完成
不适用
ENaK studyHypertensionJPRN-jRCTs031210273Katsuya Tomohiro126
已完成
2 期
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and ProteinuriaDiabetic NephropathyNCT00097955Novartis Pharmaceuticals496
已完成
不适用
Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)HypertensionNCT00749775Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3,338
尚未招募
4 期
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary AldosteronismHypertensionPrimary AldosteronismNCT05814770The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School96